Spots Global Cancer Trial Database for A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors
Official Title: A Phase 1 Dose Escalation Study of ARQ 197 Administered in Combination With Erlotinib in Adult Patients With Advanced Solid Tumors
Study ID: NCT00612703
Conditions
Interventions
Study Description
Brief Summary: To determine the safety, tolerability and recommended Phase 2 dose of ARQ 197 when administered in combination with erlotinib to patients with advanced solid tumors
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
San Diego Pacific Oncology and Hematology Associates Inc., Encinitas, California, United States
Premiere Oncology, Santa Monica, California, United States
Contact Details
Name: Lee Rosen, MD
Affiliation: Premiere Oncology of Santa Monica
Role: PRINCIPAL_INVESTIGATOR
Name: Richard G Just, MD
Affiliation: Pacific Oncology and Hematology Associates
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
